Good Distribution Practices for APIs - EU Commission Publishes Draft Guideline
Recommendation

1/2 December 2026
Bring and Keep your Organisation in Compliance with the GDP Regulations
"Guidelines on the principles of good distribution practices for active substances for medicinal products for human use" is the complete title of a guideline published for consultation by the EU Commission on its News Section a few days ago. The new guideline is addressed to distribution organisations and distributors involved in the procuring, import, exporting, holding or supplying active substances. Re-packaging, re-labelling or dividing up of batches are activities out of the scope of this guideline. These are manufacturing activities which are regulated by the principles of GMP for APIs laid down in ICH Q7 and Part 2 of the EC GMP Guide respectively.
According to the requirements of the guideline, distributors and distributing companies have to maintain a quality system. In total, the guideline contains 14 topics detailing how to elaborate this quality system:
- Quality System
- Personnel
- Documentation
- Orders
- Procedures
- Records
- Premises and equipment
- Receipt of goods
- Storage
- Deliveries
- Transfer of information
- Returns
- Complaints and recalls
- Self-inspections
Regulations for the topics named above are partly very strict. For example, all documentation - based on electronic systems - should comply with the requirements laid down in Chapter 5.4 of Part 2 of the EC GMP Guide or its Annex 11. Furthermore, the following applies to the storage conditions for APIs: they should be stored apart from other goods and - especially - under the conditions specified by the manufacturer (e.g. controlled temperature and humidity). The records regarding the monitoring of these conditions should be made and maintained periodically, and should be reviewed regularly by the person responsible for the quality system. According to the requirements on transfer of information, the customer should always receive a copy of the original active substance manufacturer. Last but not least, the distributor is obliged to conduct self-inspections to prove the implementation of and compliance with this guideline.
The draft guideline can be found in the News section of the EU Commission website and can be commented on by 30 April 2013 at the latest. Click here to open the draft document.
Related GMP News
30.09.2026European GDP Association Developments May through August 2026
30.09.2026Warehouse Temperature Excursions: What Does the FDA Expect?
30.09.2026Version 4.0 of the Swissmedic Document on Notifications of Changes Published
30.09.2026USA: Court Stops Warehouse Activities Following Persistent Insanitary Warehouse Conditions
30.09.2026GDP Non-Compliance Report: CAPA Measures must not only be Promised but also Implemented
10.09.2026Reminder: Submit your Presentation Proposal for the GDP Forum 2027 by 30 September


